Overview
Study to gather information about the optimal placement of Ra-223 in the order of different treatments in terms of the effect on patients and in terms of the use of healthcare services for the treatment of Canadian patients with prostate gland cancer which spread to other parts of the body. In order to collect this information real world data from prostate gland cancer patients from four Canadian administrative databases will be analyzed.
Eligibility
Inclusion Criteria:
- Use of at least 2 lines of life-prolonging mCRPC therapy
- The 2nd line of life-prolonging therapy was initiated between 01-Jan-2012 to 31-Dec-2017
Exclusion Criteria:
- No formal exclusion criteria will be applied in order to capture real world use of Ra-223